TY - JOUR
T1 - Current status and future of antifungal therapy for systemic mycoses.
AU - Nosanchuk, Joshua D.
PY - 2006/1
Y1 - 2006/1
N2 - Since the 1950s there has been an increase in the incidence of invasive fungal disease. The first successful systemically administered antifungal drug, amphotericin B, was introduced in the 1950s and, until very recently, was considered the best therapeutic drug for severe mycoses. The development of new antifungals to treat systemic disease has been slow compared to that of antibacterial compounds, with the introduction of only a single new class of drugs over the past 20 years. This review discusses the antifungal drugs that are clinically in use and summarizes interesting new applications and patents from the US Patent and Trademark Office.
AB - Since the 1950s there has been an increase in the incidence of invasive fungal disease. The first successful systemically administered antifungal drug, amphotericin B, was introduced in the 1950s and, until very recently, was considered the best therapeutic drug for severe mycoses. The development of new antifungals to treat systemic disease has been slow compared to that of antibacterial compounds, with the introduction of only a single new class of drugs over the past 20 years. This review discusses the antifungal drugs that are clinically in use and summarizes interesting new applications and patents from the US Patent and Trademark Office.
UR - http://www.scopus.com/inward/record.url?scp=33748933537&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748933537&partnerID=8YFLogxK
U2 - 10.2174/157489106775244109
DO - 10.2174/157489106775244109
M3 - Review article
C2 - 18221136
AN - SCOPUS:33748933537
SN - 1574-891X
VL - 1
SP - 75
EP - 84
JO - Recent patents on anti-infective drug discovery
JF - Recent patents on anti-infective drug discovery
IS - 1
ER -
